Eidos Therapeutics, Inc. Common Stock
EIDX
EIDX was delisted on the 25th of January, 2021.
91 hedge funds and large institutions have $616M invested in Eidos Therapeutics, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 37 reducing their positions, and 13 closing their positions.
6% more capital invested
Capital invested by funds: $582M → $616M (+$33.2M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
1% less funds holding
Funds holding: 92 → 91 (-1)
43% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 37
54% less call options, than puts
Call options by funds: $1.96M | Put options by funds: $4.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$10.8M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$4.69M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.66M |
| 4 |
BlackRock
New York
|
+$1.63M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$5.74M |
| 2 |
Citigroup
New York
|
-$4.78M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.79M |
| 4 |
Renaissance Technologies
New York
|
-$2.08M |
| 5 |
Millennium Management
New York
|
-$1.94M |
EIDX Hedge Fund Activity: Q3 2020 in Review
91 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics, Inc. Common Stock (EIDX) for Q3 2020, worth a combined $616M — up 5.7% from $582M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of EIDX and 12 opened new positions — a net loss of 1 holder — while 37 trimmed existing stakes and 21 added.
The largest buyer was Westfield Capital Management, opening a new position worth an estimated $10.8M. The largest seller was Redmile Group, cutting an estimated $5.74M.
- 91 institutional investors held Eidos Therapeutics, Inc. Common Stock (EIDX) as of Q3 2020, down from 92 in Q2 2020.
- Funds reported $616M of Eidos Therapeutics, Inc. Common Stock stock for Q3 2020, up 5.7% quarter-over-quarter.
- 12 funds opened new Eidos Therapeutics, Inc. Common Stock positions in Q3 2020 and 13 closed out, a net change of -1 holder.
- The largest Eidos Therapeutics, Inc. Common Stock buyer in Q3 2020 was Westfield Capital Management, an estimated $10.8M added.
- The largest Eidos Therapeutics, Inc. Common Stock seller in Q3 2020 was Redmile Group, an estimated $5.74M sold.
Based on aggregated 13F filings for Q3 2020.